01:46 , Aug 17, 2018 |  BC Innovations  |  Targets & Mechanisms

Unsaturated remyelination

Enzymes downstream in cholesterol biosynthesis could provide new ways to stimulate remyelination that avoid the baggage of previously identified multiple sclerosis targets, according to a group at Case Western. The university is spinning out Convelo...
01:59 , Dec 1, 2016 |  BC Innovations  |  Targets & Mechanisms

Not a peripheral story

By sourcing T cells directly from the pancreatic islets of Type I diabetes patients, rather than the standard method of taking blood samples, an academic team has provided an unprecedented view into the molecules that...
07:00 , Oct 24, 2016 |  BC Week In Review  |  Company News

Apitope, Merck KGaA deal

Merck returned global rights to multiple sclerosis candidate ATX-MS-1467 to Apitope, terminating the partners’ 2009 deal. The vaccine containing four synthetic peptides derived from human myelin basic protein has completed a Phase IIa trial to...
07:00 , Oct 17, 2016 |  BC Extra  |  Company News

Merck KGaA returns rights to Apitope's vaccine

Apitope International N.V. (Diepenbeek, Belgium) said Merck KGaA (Xetra:MRK) returned global rights to multiple sclerosis candidate ATX-MS-1467. Apitope did not disclose a reason for why Merck KGaA handed back the molecule. This quarter, Apitope expects...
07:00 , May 9, 2016 |  BioCentury  |  Emerging Company Profile

Deliver to the liver

Topas Therapeutics GmbH is turning a shortcoming of nanoparticles - difficulty escaping the liver - into an advantage. The company is targeting a subset of liver cells that are among the most tolerizing in the...
07:00 , Sep 28, 2015 |  BC Week In Review  |  Company News

UCSD, PsychoGenics deal

The university’s school of medicine granted PsychoGenics worldwide rights to an alpha synuclein (SNCA) transgenic mouse model to research multiple system atrophy (MSA). The Line 1 model overexpresses human wild-type SNCA under control of...
07:00 , Sep 14, 2015 |  BC Week In Review  |  Clinical News

ATX-MS-1467: Completed Phase IIa enrollment

Merck completed enrollment in an open-label, German Phase IIa trial evaluating ATX-MS-1467 for 20 weeks. Patients’ ATX-MS-1467 doses are titrated during the first 4 weeks of treatment. Merck has exclusive, worldwide rights to develop and...
07:00 , Jul 16, 2015 |  BC Innovations  |  Finance

Foundation in disrepair

The multiple sclerosis community will lose one of its advocates for investing in research on reversing the disease when the Myelin Repair Foundation (MRF) closes its doors next month due to lack of funding that...
08:00 , Jan 19, 2015 |  BioCentury  |  Emerging Company Profile

Unlocking PADs

Padlock Therapeutics Inc. is developing a pipeline of small molecule inhibitors of PAD enzymes to prevent the production of autoantigens that can trigger autoimmune diseases. The approach could selectively treat and potentially even prevent diseases...
08:00 , Dec 15, 2014 |  BC Week In Review  |  Clinical News

MyeloXen: Phase I/IIa ongoing

Xenetic said Pharmsynthez completed dosing in a 3-part, open-label, Russian Phase I/IIa trial evaluating MyeloXen in 26 subjects. The first part enrolled 6 healthy volunteers, while the second and third parts enrolled 10 patients each...